Work

Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing

Year: 2021

Type: article

Abstract: Although nintedanib is overwhelmingly prescribed to elderly patients, this is the first study to demonstrate that ageing does not impact the efficacy of nintedanib. This study sheds light on the utility of aged animal models in pulmonary fibrosis.https://bit.ly/3zA9RC5

Source: European Respiratory Journal

DOI: 10.1183/13993003.00759-2021

Authors: Kosuke Kato, Yoon-Joo Shin, Sunny Palumbo, Ioannis Papageorgiou, Seongmin Hahn, Joseph D. Irish, Skye P. Rounseville, Robert T. Krafty, Lutz Wollin, Maor Sauler, Louise Hecker

Institutions: Emory University, University of Arizona, Boehringer Ingelheim (Germany), Yale University, Atlanta VA Health Care System

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: U.S. Department of Veterans Affairs, Boehringer Ingelheim, National Institutes of Health, National Institute on Aging, National Heart, Lung, and Blood Institute, National Center for Advancing Translational Sciences

Awards: Preclinical development of a novel Nrf2-activator formulation for the treatment of idiopathic pulmonary fibrosis, G198507188, MIF and DNA repair in the emphysematous lung, Role of MIF and CD74 in the pathogenesis of emphysema, Yale Clinical and Translational Science Award

OpenAlex ID: W3200848476

FWCI: 1.297

Cites: 18

Cited by: 13

Related to: 10